• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Infectious disorders drug targets >Drug Susceptibility Testing of Mycobacterium Simiae: An Emerging Pathogen in Iran
【24h】

Drug Susceptibility Testing of Mycobacterium Simiae: An Emerging Pathogen in Iran

机译：Drug Susceptibility Testing of Mycobacterium Simiae: An Emerging Pathogen in Iran

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相关主题

摘要

Introduction: Mycobacterium simiae is an emerging pathogen in Iran and little is known about drag susceptibility patterns of this pathogen. Materials and Methods: Twenty-five clinical isolates of M. simiae from 80 patients with confirmed NTM pulmonary disease were included in this study. For drag susceptibility testing (DST), proportional and broth microdilution methods were used according to the clinical and laboratory standards institute (CLSI) guideline. Results: All clinical isolates of M. simiae were resistant to isoniazid, rifampicin, ethambutol, streptomycin, amikacin, kanamycin, ciprofloxacin, and clarithromycin. They also were highly resistant to ofloxacin (80%). Susceptibility to ofloxacin was only noted in the 5 isolates. Conclusion: Clinical isolates of M. simiae were multidrag-resistant, and had different drag susceptibility patterns than previously published studies. DST results can assist in selecting more appropriate treatment regimens. Newer drags with proven clinical efficacy correlating with in vitro susceptibility should be substituted with first- and second-line anti-TB drag testing.

著录项

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号